From 9 till 12 December 2023: HIGHLIGHTS FROM ASH
Your direct line with San Diego
From 9 till 12 December 2023, the 65th ASH (American Society of Hematology) Annual Meeting is taking place in San Diego, California. The MediMix team is onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen.
And, we also dive into posters and hot topics with both Belgian and international experts. Stay tuned!
With the educational support of:
Daily highlights
Two investigations provide novel insights into optimizing the therapeutic approach for patients with newly diagnosed multiple myeloma (NDMM) presenting high-risk features. High-risk categorization is contingent upon specific FISH abnormalities, such
We take pleasure in presenting the third daily highlight from the ASH 2023 event, featuring Evelien Krumb, a PhD candidate and medical trainee affiliated with Cliniques Universitaires Saint-Luc in Brussels.
Dr Rutger Callens, a haematologist at AZ Delta in Roeselare, graciously provided key insights into multiple myeloma. The IsKia EMN24 trial, presented in the plenary session, evaluated the efficacy and
The first daily highlight on ASH 2023 is done by Dr Bert Heyrman, haematologist at the ZNA Hospitals, Antwerp. He selected 4 presentations from the session on Myeloid Malignancies:
In-depth stories
Dr Evren Alici, principal researcher and head of the cell and gene therapy group at the Karolinska Institute in Stockholm, Sweden was so kind to summarise data on NK cell
In this presentation, data sourced from the CIBM-TR registry were utilized to assess the differential outcomes of Brexu-cel therapy in patients with R/R MCL exhibiting high-risk features, such as delTP53/17P,
At the ASH meeting, Professor Oliva presented the patient-reported outcomes from the QuANTUM-First trial, a phase 3 clinical investigation assessing the efficacy and safety of quizartinib. Quizartinib, is approved in
Prof Claudio Cerchione, haematologist at the Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy, was so kind to share his highlights on multiple myeloma from
KarMMa-3 constitutes an open-label, phase 3 randomized clinical trial aimed at investigating the efficacy of a single infusion of the BCMA-targeting CAR-T cell product ide-cel in comparison to conventional standard-of-care
Dr Rutger Callens, a haematologist at AZ Delta in Roeselare, delved into the intricacies of emerging therapeutic targets in multiple myeloma (MM), weighing the pros and cons associated with these
BTKi has demonstrated efficacy in MCL; however, a substantial number of patients experience relapse during treatment. Pirtobrutinib, a non-covalent third-generation BTKi, exhibits enhanced effectiveness in the post-covalent BTKi setting and
Dr Annemiek Broijl, haematologist at the Erasmus MC hospital in Rotterdam, the Netherlands and co-principal investigator of the IsKia study was so kind to present the results. The study aims
Hemophilia recognized as a disorder characterized by excessive bleeding, has conventionally been considered exclusive to male individuals. However, emerging research highlights the potential manifestation of haemophilia in females who carry
Dr Fred Locke from Moffitt Cancer Center in Florida shares the data that were presented at the oral session on real world data of cellular therapies for B cell lymphomas
The current standard of care for patients with NDMM involves four cycles of VRd induction pre-ASCT, followed by two VRd cycles of consolidation post-ASCT, and subsequently, a maintenance phase with
The ZUMA-12 study represents a phase 2 clinical trial aimed at investigating the efficacy of Axi-Cel as a primary therapeutic intervention for individuals diagnosed with high-risk LBCL. High-risk categorization involved
Allogeneic CAR T-cell therapies represent a potentially readily accessible therapeutic alternative derived from healthy donors. However, ensuring a secure and efficient method to regulate host lymphocyte rejection (allo-rejection) is imperative.<br
The therapeutic potential of inhibiting NETs in various pathological conditions is elucidated in a scientific discourse by Dr Martinod. Dr Martinod’s research primarily delves into the PAD4 molecule’s involvement in
Dr Sharman presents the 6-year follow-up outcomes of the ELEVATE-TN study, a prospective, randomized phase 3 investigation involving previously untreated patients with CLL. Three cohorts were subjected to distinct treatments:
Poster selection
Dr Cesar Rodriguez, affiliated with Mount Sinai in New York, presents a research study examining the impact of isatuximab (Isa) on the occurrence of hypogammaglobulinemia (HGG) and the concomitant risk
In this study, Dr Aaron Goldberg from the Memorial Sloan Kettering Cancer Center presents a comparative analysis of outcomes and healthcare research utilization in patients with AML treated with venetoclax
Prof George Follows, a consulting haematologist from Nuffield Health Cambridge Hospital, presents a post-hoc analysis of the ELEVATE-TN trial, a prospective, randomized study involving treatment-naïve elderly CLL patients. Patients were
In this presentation, Dory Abelman, a PhD candidate at the Princess Margaret Cancer Centre, University of Toronto, assesses the concordance of molecular profiles between cancer cells derived from bone marrow
Dr Betsy O’Donnell, a haematologist at the Dana-Farber Cancer Institute (US), presents the findings from the SKylaRK trial, a phase 2 study in NDMM patients eligible for transplantation, who received
Prof Claire Harrison, a haematologist at Guy’s and St. Thomas’ Hospital in London (UK), presents collaborative efforts involving colleagues and patients to offer pragmatic recommendations for treating patients with myelofibrosis,
Dr Frida Bugge Askeland, associated research doctor and PhD student at the Oslo Myeloma Center in Norway outlined the REMNANT study.
The REMNANT study aims to assess whether addressing MRD relapses
Dr Gabriel Brisou presents preliminary findings on the utilization of axi-cel in the second-line treatment of patients with early R/R LBCL. In France, real-world data encompassing all patients subjected to
Dr Cecilie Blimark, haematologist at the Sahlgrenska University Hospital in Sweden summarized her extensive population-based investigation encompassing symptomatic MM patients from the Swedish Myeloma Registry, ensuring a robust 98% coverage
Dr Margo Aertgeerts from UZ Leuven presented her PhD research in ALL, the most prevalent cancer in the pediatric population. The aetiology of ALL involves the incremental acquisition of mutations
T-ALL represents a highly aggressive haematological malignancy, characterized by an unmet clinical need, particularly in refractory patients or those resistant to standard treatments. Dr Tim Pieters, PhD at Ghent University
André De Almeida, PhD student at the University Hospital Ghent presented his research on investigating the role of SOX11 in T-ALL, which is motivated by its expression within a distinct
Approximately 30% of pediatric AML patients encounter relapse, emphasizing the imperative need for refining risk stratification in this cohort. Consequently, Zhiyao Ren, PhD student at University Hospital Ghent, constructed a
An innovative decentralized and automated PoC manufacturing paradigm was devised to facilitate the expeditious administration of freshly prepared autologous CAR-T therapies within a 7-day timeframe following apheresis in patients diagnosed
Dr Frida Bugge Askeland, associated research doctor and PhD student at the Oslo Myeloma Center in Norway summarised the REST study.
In Norway, the use of VRd (bortezomib, lenalidomide and